Mednet Logo
HomeHematology
Hematology

Hematology

Clinical discussions on blood disorders, coagulation, transfusion medicine, and hematologic malignancies.

Recent Discussions

How do you manage a patient with sickle cell disease during pregnancy?

1
2 Answers

Mednet Member
Mednet Member
Hematology · University of Pittsburgh

I refer all pregnant women with SCD to maternofetal medicine/high risk pregnancy clinic for more frequent monitoring. I recommend a baby aspirin for preeclampsia prevention (see UK guidelines). I recommend folic acid 4 mg. If they do have iron overload, I do not recommend iron supplementation. For a...

How do you manage endocrine therapy for premenopausal women with breast cancer who are heterozygous for factor V Leiden but have no history of thrombosis?

3
1 Answers

Mednet Member
Mednet Member
Medical Oncology · Penn Medicine, University of Pennsylvania Health System

This is a difficult situation given that the literature is contradictory on this topic. Both tamoxifen and a factor V Leiden mutation independently increase risk of thromboembolic events. It is unclear whether, together, they would be additive in conferring risk of thrombosis. Dr. Cuzick wrote a ver...

Do you choose to include or omit growth factor support in the treatment of Hodgkins lymphoma?

1 Answers

Mednet Member
Mednet Member
Medical Oncology · University of Mississippi Medical Center

I typically do not use "up front" growth factor support unless my patient is frail. If symptomatic neutropenia develops during therapy I will add growth factor support at that time. For the patient with asymptomatic neutropenia I will continue therapy and individualize the decision for the addition ...

How do you approach a patient with high titer ANA and a new diagnosis of ITP, but no other signs or symptoms suggestive of active rheumatologic disease?

3
5 Answers

Mednet Member
Mednet Member
Rheumatology · UTMB Health

I would certainly treat the ITP with hematology involvement if necessary but would continue to monitor for lupus or similar CTDs. I have seen patients present with an ITP-like picture for years before lupus declared itself eventually. It may take years. I would also check a UA for proteinuria. This ...

How do you incorporate CAR-T cell therapy for DLBCL in transplant-eligible patients?

6 Answers

Mednet Member
Mednet Member
Medical Oncology · The Ohio State University College of Medicine

The role of sequential therapy including CARs vs high dose chemotherapy + ASCT post primary induction failure/relapse in large cell lymphoma is a matter of active research. Given the present FDA indication of CARs is in relapsed/refractory large cell lymphoma after failure of at least 2 lines of pri...

Does stopping anagrelide affect fibrosis in patients with ET who develop post-ET myelofibrosis?

1 Answers

Mednet Member
Mednet Member
Hematology · Johns Hopkins University

Anagrelide is a phosphodiesterase (PDE) III inhibitor, developed initially as a platelet antiaggregant, but was found to have platelet lowering activity at concentrations lower than its platelet antiaggregant activity. Thus, it was consequently marketed to reduce thrombocytosis in MPN patients. It i...

Would you recommend an allogenic stem cell transplant in an older patient > 50 with Ph negative acute lymphoblastic leukemia who is MRD negative after induction?

1
2 Answers

Mednet Member
Mednet Member
Medical Oncology · University of Washington

In general, I would not routinely recommend allogeneic hematopoietic cell transplantation (HCT) for Ph- acute lymphoblastic leukemia (ALL) that is in MRD-negative remission this early in their treatment. This sort of response demonstrates significant chemosensitivity. Therefore, I would favor contin...

Are you more permissive of perioperative interruption of anticoagulation for VTE depending on the location and relative chronicity of the thrombus?

2
1 Answers

Mednet Member
Mednet Member
Hematology · BIDMC

Yes - in general, I try to balance the relative urgency/importance of the procedure or surgery v. the thrombotic risk to the patient of a period of time off of anticoagulation. Location and chronicity both can feed into determining thrombotic risk. An upper extremity DVT, in general, has a lower rec...

How would you manage symptomatic superficial vein thrombosis during pregnancy?

2 Answers

Mednet Member
Mednet Member
Hematology · Medical University of South Carolina

The best evidence for the treatment of SVT comes from the CALISTO trial, which endorsed a prophylactic dose of fondaparinux as the treatment of choice. However, the CALISTO trial excluded pregnant women. Because data on the use of fondaparinux in pregnancy remain limited, with some traces of fondapa...

When should you use caplacizumab in the treatment of acute TTP patients?

2 Answers

Mednet Member
Mednet Member
Hematology · University of Pittsburgh

Whenever I encounter a patient with features of thrombotic microangiopathy and a normal coagulation panel (that rules out DIC), I consider the possibility they may have immune TTP.If my suspicion of immune TTP is high (e.g. history of autoimmune disease, possible relapse of immune TTP) and there is ...